Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can Biosimilars Compete With ‘Unbranded Biologics’ In The US Market?

Apr 14 2021

• By Derrick Gingery

Insulin vials with synringe — Two sponsors already are marketing insulin products as 'unbranded biologics.' • Source: Shutterstock

Related Content

Lilly Adds Two More Humalog Authorized Generics As Insurance Deductibles Reset

Jan 14 2020

The Last Days Of NDAs: Uncertainties Remain Ahead Of 23 March Move From Drugs To Biologics

Mar 16 2020

'Authorized Biosimilars' Can't Use 351(k) Pathway, US FDA Concludes

Mar 05 2020

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

Nov 18 2020

CDER Planning Guidances On Single-Trial Approvals, Real-World Evidence

Jan 26 2021

Novo Nordisk Launches Low-Priced Insulin In US

Jan 14 2020

US Prescribers Embrace Oncology Biosimilars; How Will Humira Follow-Ons Fare?

Feb 10 2021

Related Companies

Teva Pharmaceuticals USA Inc.

Novo Nordisk A/S

Eli Lilly and Company

Additional Topics

United States Biosimilars Review Pathway Regulation Biologics BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window